Private Capital Advisors Inc. cut its stake in Eli Lilly and Co (NYSE:LLY) by 0.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 385,549 shares of the company’s stock after selling 2,990 shares during the quarter. Eli Lilly and comprises about 11.3% of Private Capital Advisors Inc.’s investment portfolio, making the stock its biggest position. Private Capital Advisors Inc.’s holdings in Eli Lilly and were worth $32,563,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently added to or reduced their stakes in the business. Accredited Investors Inc. raised its position in Eli Lilly and by 0.4% in the second quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock valued at $268,000 after purchasing an additional 14 shares during the period. Oakworth Capital Inc. raised its position in Eli Lilly and by 0.3% in the second quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock valued at $552,000 after purchasing an additional 20 shares during the period. Sfmg LLC raised its position in Eli Lilly and by 0.5% in the second quarter. Sfmg LLC now owns 4,258 shares of the company’s stock valued at $350,000 after purchasing an additional 20 shares during the period. Jackson Grant Investment Advisers Inc. raised its position in Eli Lilly and by 0.7% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 3,647 shares of the company’s stock valued at $300,000 after purchasing an additional 24 shares during the period. Finally, YorkBridge Wealth Partners LLC raised its position in Eli Lilly and by 0.8% in the second quarter. YorkBridge Wealth Partners LLC now owns 3,199 shares of the company’s stock valued at $265,000 after purchasing an additional 24 shares during the period. 76.31% of the stock is currently owned by institutional investors.

Eli Lilly and Co (NYSE:LLY) traded up $0.59 during trading hours on Friday, reaching $86.98. The company had a trading volume of 2,728,878 shares, compared to its average volume of 2,741,344. The firm has a market capitalization of $95,770.00, a P/E ratio of 41.42, a price-to-earnings-growth ratio of 1.62 and a beta of 0.35. Eli Lilly and Co has a fifty-two week low of $74.00 and a fifty-two week high of $89.09. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.02. The business had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The company’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same period last year, the firm earned $0.88 earnings per share. analysts expect that Eli Lilly and Co will post 4.22 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be paid a $0.5625 dividend. This represents a $2.25 dividend on an annualized basis and a yield of 2.59%. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio (DPR) is 99.05%.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 200,000 shares of Eli Lilly and stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total value of $17,640,000.00. Following the completion of the transaction, the insider now directly owns 123,084,104 shares in the company, valued at $10,856,017,972.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Jeffrey N. Simmons sold 12,500 shares of Eli Lilly and stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $86.46, for a total value of $1,080,750.00. Following the completion of the transaction, the senior vice president now owns 124,522 shares of the company’s stock, valued at $10,766,172.12. The disclosure for this sale can be found here. Insiders sold 251,088 shares of company stock valued at $22,041,236 over the last quarter. Insiders own 0.20% of the company’s stock.

Several research firms have commented on LLY. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 target price for the company in a research note on Thursday, October 26th. Piper Jaffray Companies restated a “buy” rating and set a $105.00 target price on shares of Eli Lilly and in a research note on Friday, October 13th. Goldman Sachs Group restated a “buy” rating and set a $95.00 target price (up from $92.00) on shares of Eli Lilly and in a research note on Thursday, October 5th. Cowen restated a “buy” rating and set a $95.00 target price on shares of Eli Lilly and in a research note on Wednesday, October 4th. Finally, Berenberg Bank restated a “buy” rating and set a $98.00 target price on shares of Eli Lilly and in a research note on Thursday, October 26th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and ten have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $92.14.

ILLEGAL ACTIVITY NOTICE: “Private Capital Advisors Inc. Has $32.56 Million Holdings in Eli Lilly and Co (LLY)” was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2018/01/12/private-capital-advisors-inc-has-32-56-million-holdings-in-eli-lilly-and-co-lly.html.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.